EGFR and lung carcinoma: Based on the clinical guidelines outlined by the National Comprehensive Cancer Network (NCCN) for the treatment of lung cancer, patients with tumors harboring activating mutations in the epidermal growth factor receptor (EGFR) gene require therapy with tyrosine kinase inhibitors (TKIs) [4,5,6].